First Trade Date for IDEC Pharmaceuticals Corp.
| Company Name | First Trade Date (yyyy-mm-dd) |
| IDEC Pharmaceuticals Corp. | 1991-09-17 |
| Company Name | Symbol |
| IDEC Pharmaceuticals Corp. | IDPH |
| History and Business of Company (this information may include date of incorporation) | |
|
IDEC Pharmaceuticals Corp. (IDPH) is a biopharmaceutical company that is commercializing, researching and developing therapies to treat cancers and autoimmune and inflammatory diseases. The company's first commercial product is Rituxan. Rituxan and its most advanced product candidate, Zevalin, are both targeted for the treatment of non-Hodgkin's B-cell lymphomas, which afflict approximately 300,000 patients in the U.S. IDPH is also developing products for the treatment of solid tumors, lupus and psoriasis. The company is also developing products for the treatment of various autoimmune diseases such as psoriasis and rheumatoid arthritis. Rituxan received regulatory approval in the U.S. and Switzerland in November 1997 for single agent use in certain types of B-cell non-Hodgkin's lymphomas. Rituxan is the U.S. trade name for the compound Rituximab (formerly IDEC-C2B8). Rituxan is being marketed and sold in the U.S. and Canada under a co-promotion agreement with Genentech, Inc. Outside the U.S., Rituxan is marketed by Hoffman-La Roche Ltd. under the name MabThera, except in Japan, where it is marketed by Zenyaku Kogyo Co. Ltd. IDPH has five additional product candidates in various stages of clinical testing, the most advanced of which is Zevalin, a radioimmunotherapy proposed for the treatment of B-cell NHL. Zevalin has completed two Phase III human clinical trials, and a biological license application is pending with the FDA. Other antibodies in development include Primatized Anti-CD4 (IDEC-151), for treatment of rheumatoid arthritis; Humanized Anti-CD40L (UDEC- 131), for treatment of autoimmune diseases; Primatized Anti-B7.1 (IDEC-114), as a treatment for psoriasis; and Primatized Anti-CD23 (IDEC-152), as a treatment for allergic asthma. IDPH has discovered a proprietary antigen formulation, PROVAX, that has shown the ability to induce cellular immunity in animals immunized with protein antigens. Cellular immunity is a counterpart to antibody-based immunity, and is responsible for the direct destruction of virally infected and malignant cells. PROVAX is a combination of defined chemical entities and may provide a practical means for the development of effective immunotherapies, which the company believes may be useful for the treatment of certain cancers and viral diseases. The company intends to make PROVAX available through licenses and collaborations to interested parties for development of immunotherapeutic vaccines. The company intends to continue its preclinical development of PROVAX in 2002. INCORPORATED in Delaware May 22, 1997, succeeding previous incorporation in California July 19, 1985 as Robisol Corp.; name changed to IDEC Pharmaecuticals Corp. in September 1986. OFFICE- 3030 Callan Rd., San Diego, CA, USA 92121 (Tel.: 858-431-8500). Fax - 858-431-8750. WEBSITE-http://www.idecpharm.com. | |
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
© 1999-2004 by Magi Astrologers Worldwide Corporation. All Rights Reserved.